# A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy

> **NCT02057341** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 12 (actual)

## Conditions studied

- LMNA-Related Dilated Cardiomyopathy

## Interventions

- **DRUG:** ARRY-371797, p38 inhibitor; oral

## Key facts

- **NCT ID:** NCT02057341
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02057341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02057341, "A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02057341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*